*  DC vaccination as post-remission therapy in AML | AML Global Portal
... which correlated with the induction of WT1-specific CD8+ T-cell responses. ... Vaccination of AML patients in remission with WT1 mRNA-electroporated DCs lead to improved OS rates, ... Post-remission therapy with DC vaccination in AML. Cynthia Umukoro , Sep 1, 2017 , Expert Opinion. ... et al. Dendritic cell vaccination as post-remission treatment to prevent or delay relapse in acute myeloid leukemia. Blood. ...
  http://www.amlglobalportal.com/medical-information/post-remission-therapy-with-dc-vaccination-in-aml
*  Acute lymphoblastic leukemia in adults: recent progress, future directions
Most patients, greater than 70% to 80%, will achieve a remission following induction chemotherapy with vincristine, prednisone ... Additional drugs do not convincingly increase the remission rate; their effect on remission duration is unknown. Although ... continuation therapy has not been critically evaluated in randomized trials, the longest remissions have been reported in ...
  https://imsdd.meb.uni-bonn.de/cgi-bin/mycite?ExtRef=MEDL/87149134/PMID/3547671
*  Adult Acute Lymphoblastic Leukemia: Remission Induction - UNM Comprehensive Cancer Center
Therapy is divided into two phases, remission induction and post-remission therapy. Remission induction chemotherapy is ... remission induction rate following remission induction treatment with Cerubidine® (daunorubicin), Oncovin, prednisone, and ... Following remission induction with hyper-CVAD the complete remission rate in older patients was 84% compared to 92% in younger ... Strategies to Improve Remission Induction. The development of intensive multi-agent chemotherapy induction regimens, ...
  http://cancer.unm.edu/2008/10/01/adult-acute-lymphoblastic-leukemia-remission-induction/
*  P609 Efficacy of cytapheresis for remission induction therapy and dermatological manifestations of active ulcerative colitis
Remission induction rate, corticosteroid sparing, and the response to skin lesions were factored into our assessment of ... P609 Efficacy of cytapheresis for remission induction therapy and dermatological manifestations of active ulcerative colitis O ... This study was to assess the efficacy of cytapheresis for remission induction and dermatological manifestations of active UC. ... In this study, cytapheresis was effective as remission induction therapy with significant steroid sparing effect. Additionally ...
  https://www.ecco-ibd.eu/publications/congress-abstract-s/abstracts-2015/item/p609-efficacy-of-cytapheresis-for-remission-induction-therapy-and-dermatological-manifestations-of-active-ulcerative-colitis.html
*  AB0465 Early remission induction and outcome in primary medium and small vessel vasculitis - retrospective review of ten years...
Rituximab has achieved remission in refractory vasculitis. Aggressive early induction therapy and sustained remission have ... AB0465 Early remission induction and outcome in primary medium and small vessel vasculitis - retrospective review of ten years ... AB0465 Early remission induction and outcome in primary medium and small vessel vasculitis - retrospective review of ten years ... treatment outcomes and to assess the impact of early remission induction therapy. ...
  http://ard.bmj.com/content/72/Suppl_3/A930.3
*  Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis - Tabular View - ClinicalTrials.gov
Cyclosporine-A Versus Prednisolone for Induction of Remission in Auto-immune Hepatitis. The safety and scientific validity of ... Prednisolone for Induction of Remission in Auto-immune Hepatitis. Brief Summary Untreated Autoimmune hepatitis (AIH) is a ... Alternative options for induction of remission are limited. There are reports of successful salvage therapy with Cyclosporine-A ... The investigators aim to assess the efficacy and tolerability of CsA directly to the CS for induction of remission in treatment ...
  https://clinicaltrials.gov/ct2/show/record/NCT01170351
*  5-ASA suppositories, enemas or foam for induction of remission in ulcerative colitis | Cochrane
5-ASA suppositories, enemas or foam for induction of remission in ulcerative colitis. Ulcerative colitis (UC) is a chronic ... Cyclosporine A for induction of remission in severe ulcerative colitis. *Methotrexate for treatment of chronic active ... Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2010, ... endoscopic remission 5.31 (7 trials, 95% CI 3.15 to 8.92; P , 0.00001), and histologic remission 6.28 (5 trials, 95% CI 2.74 to ...
  http://www.cochrane.org/CD004115/IBD_5-asa-suppositories-enemas-or-foam-for-induction-of-remission-in-ulcerative-colitis
*  Traditional Chinese medicinal herbs for induction of remission in advanced or late gastric cancer | Cochrane
Traditional Chinese medicinal herbs for induction of remission in advanced or late gastric cancer. Gastric cancer, one of the ... Yang J, Zhu L, Wu Z, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane ... Although some chemotherapies or bio-therapies have made progress in the remission of this disease, the mortality from gastric ... To assess the effectiveness of Chinese medicinal herbs in the short-term remission of advanced or late gastric cancer. ...
  http://www.cochrane.org/CD005096/UPPERGI_traditional-chinese-medicinal-herbs-for-induction-of-remission-in-advanced-or-late-gastric-cancer
*  Chinese herbal medicines for induction of remission in advanced or late gastric cancer - The Cochrane Library - Yang - Wiley...
Yang J, Zhu L, Wu Z, Wang Y. Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Cochrane ... Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Tao Gan, Zongying Wu, Ling Tian and ... Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Tao Gan, Zongying Wu, Ling Tian and ... Chinese herbal medicines for induction of remission in advanced or late gastric cancer. Jinlin Yang, Linlin Zhu, Zongying Wu ...
  http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005096.pub4/otherversions
*  Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease - Full Text View -...
Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease. The safety and scientific validity ... A Randomized, Single Blinded, Controlled, Multi Center Phase 4 Study for Induction of Remission in Active Pediatric Crohn's ... Background: Recent reviews and guidelines no longer recommend antibiotic therapy for induction of remission in Crohn's disease ... Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric ...
  https://clinicaltrials.gov/ct2/show/NCT01596894?recr=Open&cond=%22Crohn+Disease%22&rank=15
*  Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis - Full Text View ...
Allogeneic Adipose Tissue-derived Mesenchymal Stem Cells for the Induction of Remission in Ulcerative Colitis (ALOASCU). The ... Remission will be considered if reaches 0 points and response if the score diminishes. Endoscopy will be performed at 0 and 8 ... Remission will be considered if it descends below 11, and response if it diminishes at least 30%. Modified Truelove-Witts score ... on Induction to Remission in Ulcerative Colitis. ... to evaluate the efficacy of the treatment to induce remission ...
  https://clinicaltrials.gov/ct2/show/NCT01914887?recr=Open&cond=%22Colitis%2C+Ulcerative%22&rank=19
*  BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of...
Induction of clinical remission [ Time Frame: 24 weeks ]. Clinical remission includes the ability to taper corticosteroids. ... safety and tolerability of blisibimod when taken with methotrexate in the induction of remission in ANCA-Associated Small ... and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small ... and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small ...
  https://clinicaltrials.gov/ct2/show/NCT01598857?recr=Open&cond=%22Granulomatosis+with+Polyangiitis%22&rank=6
*  SP0189 Induction of Remission by Low-Dose IL-2-Therapy in One SLE Patient with Increased Disease Activity Refractory to...
SP0189 Induction of Remission by Low-Dose IL-2-Therapy in One SLE Patient with Increased Disease Activity Refractory to ... SP0189 Induction of Remission by Low-Dose IL-2-Therapy in One SLE Patient with Increased Disease Activity Refractory to ...
  http://ard.bmj.com/content/73/Suppl_2/50.1
*  Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease - Full...
Efficacy (Induction of Response/Remission) and Safety Study in Patients With Moderate to Severe Crohn's Disease. This study has ... To induce clinical remission and/or clinical response following 8 weeks of treatment [ Time Frame: 8 weeks ]. ... The purpose of this study is to evaluate if Leukine can induce clinical response or remission in patients with Crohn's disease. ... Randomized, Double-Blind, Placebo-Controlled, Phase 3 Induction Study to Assess the Efficacy and Safety of 6µg Sargramostim ( ...
  https://clinicaltrials.gov/ct2/show/NCT00295165
*  Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis, Digestive Diseases and...
"Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis, Digestive Diseases and ... Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis. Fernández-Blanco, J.; ... Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative... Fernández-Blanco, J.; ... Adalimumab for Induction of Histological Remission in Moderately to Severely Active Ulcerative Colitis. ...
  https://www.deepdyve.com/lp/springer_journal/adalimumab-for-induction-of-histological-remission-in-moderately-to-4Brd5Ioz2J
*  Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease - Mayo...
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease. * Print ... Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to ... The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance ...
  http://www.mayo.edu/research/clinical-trials/cls-20307291
*  Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute...
... induction remission rate than daunorubicin in de novo acute myeloid leukemia patients.Whether induction therapy with IA regimen ... has a higher remission quality with AML patients than that of DA regimen in high MDR1 expression AML patients. ... induction remission rate than daunorubicin in de novo acute myeloid leukemia patients.Whether induction therapy with IA regimen ... Idarubicin Overcomes MDR1 Induced Chemoresistance With Higher Induction Remission Rate and Quality Than Daunorubicin in Acute ...
  https://www.careacross.com/clinical-trials/trial/NCT01889407
*  Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease - Full...
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease. The safety ... Number of Participants in Clinical Remission at Treatment Week 20. Clinical Remission Defined as Harvey Bradshaw Index (HBI) ... Clinical remission = HBI less than 5. Highest total score at Baseline was 47. Missing data were imputed using non-responder ... Study of the Fully Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in ...
  https://clinicaltrials.gov/show/NCT00409617
*  A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic...
Proportion of subjects who achieve remission at Week 52 [ Time Frame: Week 52 ]. Remission to be determined at Week 52 ... Active Comparator: Induction Period ABT-494 Low/Medium Dose Induction Period ABT-494 Low/Medium Dose orally dosed twice a day ... Active Comparator: Induction Period ABT-494 Twice Daily Medium/High Dose Induction Period ABT-494 Twice Daily Medium/High Dose ... Active Comparator: Induction Period ABT-494 Once Daily Medium/High Dose Induction Period ABT-494 Once Daily Medium/High Dose ...
  https://www.clinicaltrials.gov/ct2/show/NCT02365649?term=m13-740&rank=1
*  Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center...
Primary endpoints were remission induction, occurrence of relapses, prednisolone (PSL) dosage at time of remission, and adverse ... Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center ... Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center ... Interferon-α for Induction and Maintenance of Remission in Eosinophilic Granulomatosis with Polyangiitis: A Single-center ...
  http://www.jrheum.org/content/44/6/806
*  Delay to institution of therapy and induction of remission using single-drug or combination-disease-modifying antirheumatic...
The presence of a shared epitope was not related to the induction of remission. CONCLUSION The delay of a few months from the ... RESULTS The delay to therapy (cut point of 4 months) was the only significant predictor for remission in patients treated using ... The frequency of achieving remission in the combination-DMARD group after 2 years was similar in patients with short (0-4 ... on the prediction of disease remission after 2 years in patients with early rheumatoid arthritis (RA). METHODS In the FIN-RACo ...
  https://www.semanticscholar.org/paper/Delay-to-institution-of-therapy-and-induction-of-or-M%C3%B6tt%C3%B6nen-Hannonen/c87169e678eacce7c5704701c644de90c290f039
*  229 Mycophenolate mofetil for induction of remission in lupus enteritis | Lupus Science & Medicine
Conclusions Mycophenolate mofetil (MMF) appears promising as an agent of remission induction and maintenance in patients with ... their in vitro expression.The aim of study was to determine the efficacy of Mycophenolate mofetil in the induction of remission ... Subsequently, Mycophenolate mofetil 1000 mg twice a day was added in the regimen for remission. Only 1 patient developed ... All patients received induction with high dose pulse methylprednisone 1000 mg IV for three days followed by prednisone at a ...
  http://lupus.bmj.com/content/4/Suppl_1/A105.2
*  Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. -...
... cyclophosphamide for remission induction of antineutrophil cytoplasm autoantibodies-associated systemic vasculitis when both ... Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. Share ... Pulse versus daily oral cyclophosphamide for induction of remission in ANCA-associated vasculitis: long-term follow-up. ... Remission Induction, Administration, Oral, Pulse Therapy, Drug, Risk Factors, Retrospective Studies, Follow-Up Studies, Time ...
  https://www.ndorms.ox.ac.uk/publications/216096
*  A Multicenter, Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission...
... who are in complete remission following initial chemotherapy, live ... Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission After Induction ... Phase 2 Study of Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia in Complete Remission After Induction ...
  http://adisinsight.springer.com/trials/700014243?error=cookies_not_supported&code=d997c051-d042-4146-b663-2eb69681eeb4
*  A multicenter, retrospective, cohort study to evaluate the efficacy and safety of rituximab and glucocorticoid therapy for...
... cohort study to investigate the clinical outcomes and safety of rituximab and glucocorticoid therapy for induction of remission ... cohort study to evaluate the efficacy and safety of rituximab and glucocorticoid therapy for induction of remission in patients ... cohort study to evaluate the efficacy and safety of rituximab and glucocorticoid therapy for induction of remission in patients ...
  https://adisinsight.springer.com/trials/700270955?error=cookies_not_supported&code=942d471d-ce7b-430d-8800-1652806b8d2f